BAE-SYSTEMS
16.12.2022 10:02:34 CET | Business Wire | Press release
Sweden, Germany, and the United Kingdom have reached an agreement with BAE Systems to purchase 436 BvS10 all-terrain vehicles. The joint procurement, worth $760 million, is in support of Arctic operations for the Collaborative All-Terrain Vehicle (CATV) program.
BAE Systems’ military all-terrain vehicles are designed for operations in the harshest and most remote environments and this agreement signals the Company’s position as the defense industry’s leader for these capabilities.
“We‘re seeing increased interest from numerous countries for the extreme mobility capabilities offered by the BvS10 and its unarmored sister vehicle, Beowulf,” said Tommy Gustafsson-Rask, managing director of BAE Systems Hägglunds, which manufactures the vehicles in Örnsköldsvik, Sweden. “Sweden, Germany, and the United Kingdom will be getting an excellent return on their investment in these highly capable vehicles for decades to come. This further demonstrates the strong relationship between BAE Systems and our customers to deliver these critical capabilities.”
The three-nation acquisition will deliver the 436 vehicles beginning in 2024, with 236 BvS10s going to the Swedish Defense Materiel Administration (FMV), 140 to the German Federal Ministry of Defence (BAAINBw), and 60 to the United Kingdom Ministry of Defence (MoD). The vehicles are based on the latest version of the BvS10 currently operated by Sweden, and will include variants for troop transport, logistics, medical evacuation, recovery, and command and control.
The CATV program includes a framework agreement that could lead to the purchase of more vehicles by the three nations, keeping the BvS10, the world’s leading all-terrain vehicle, in production for many years to come. Sweden is the lead nation and has established a joint procurement office to lead the effort with representatives from all three nations.
This acquisition follows Sweden’s order last year of an additional 127 BvS10 all-terrain vehicles for its existing fleet. In parallel to this agreement, Sweden is also procuring an additional 40 BvS10s in a separate contract valued at approximately $50 million.
The BvS10 and Beowulf are the world leaders when it comes to all-terrain solutions. Their articulated mobility systems provide optimal maneuverability across varying terrains so they can traverse snow, ice, rock, sand, mud or swamps, as well as steep mountain environments. The vehicles’ amphibious feature also allow them to swim in flooded areas or coastal waters.
The vehicles can deliver personnel and supplies to sustain strategic, tactical, and operational mobility.
BvS10’s unprecedented mobility is based on terrain accessible North Atlantic Treaty Organization (NATO) standards. Its modular design allows it to be reconfigured for varying missions and can be delivered in multiple variants that include carrying personnel, command and control, ambulance, vehicle repair and recovery, logistics support, situational awareness, and a weapons carrier with additional mortar capability.
BvS10 is currently operated by Austria, France, the Netherlands, Sweden, and the United Kingdom. BAE Systems’ Beowulf, the unarmored variant of the BvS10, won the U.S. Army’s competition for its Cold Weather All-Terrain Vehicle (CATV) program in August. The U.S. Army will receive 110 vehicles over a five-year period.
Issued by:
BAE Systems, Inc.
www.baesystems.com
@BAESystemsInc
For associated imagery, please visit: https://baesys.resourcespace.com/?c=16201&k=d788ec24d8
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221216005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
